Jazz Pharmaceuticals is actively exploring mergers and acquisitions (M&A) of different sizes, according to company executives. Meanwhile, they are concluding legal battles over the patents for Epidiolex, a medication used to treat certain types of seizures.
Just one minute into his prepared speech during Jazz Pharmaceuticals’ fourth-quarter earnings call, CEO Bruce Cozadd highlighted the company’s interest in making deals.